SEC Comment Letter for Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Dec 13, 2018
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Dec. 13, 2018 · CIK: 0001645469 · Accession: 0000000000-18-037949
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-55866
Letter
December 13, 2018 Kim R. Tsuchimoto Chief Financial Officer Monopar Therapeutics Inc. 1000 Skokie Blvd. Suite 350 Wilmette, Illinois 60091 Re:Monopar Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed March 26, 2018 and Amended December 11, 2018 File No 000-55866 Dear Ms. Tsuchimoto: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
December 13, 2018
Kim R. Tsuchimoto
Chief Financial Officer
Monopar Therapeutics Inc.
1000 Skokie Blvd.
Suite 350
Wilmette, Illinois 60091
Re:Monopar Therapeutics Inc.
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed March 26, 2018 and Amended December 11, 2018
File No 000-55866
Dear Ms. Tsuchimoto:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance